)
Visual24 Oct 2025
The rise of Alphabet
Nanobiotix (NANO) investor relations material
Nanobiotix H1 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2025 earnings summary30 Sep, 2025
Executive summary
Focused on clinical development of JNJ-1900 (NBTXR3) for head and neck, lung, pancreatic, and melanoma cancers, with strategic partnership and sponsorship transfer to Janssen (J&J).
Achieved regulatory harmonization in Europe, reclassifying JNJ-1900 (NBTXR3) as a drug.
Strengthened intellectual property with a new composition of matter patent filing.
Positive clinical data in lung and pancreatic cancer, with promising survival rates and safety profile.
Amended license agreement with Janssen, transferring most financial responsibility for the pivotal Phase 3 trial and reducing future milestone payments.
Financial highlights
Revenue and other operating income for H1 2025 reached €26.6M, up from €9.3M in H1 2024, mainly due to a €21.2M one-time gain from the Janssen contract amendment.
Operating expenses decreased to €25.8M from €32.9M year-over-year, with R&D spend dropping due to the transfer of trial sponsorship.
Net loss narrowed to €5.4M (€0.11 per share) from €21.9M (€0.46 per share) year-over-year.
Cash and equivalents at June 30, 2025, were €28.8M, down from €49.7M at year-end 2024.
SG&A expenses were €11.3M, stable compared to €10.8M in H1 2024.
Outlook and guidance
Cash and cash equivalents are expected to fund operations into mid-2026, but an additional €8–10M is needed to cover the next 12 months.
Ongoing discussions for non-dilutive financing to extend the cash runway beyond mid-2026; may seek further capital via equity, partnerships, or grants.
Future revenue depends on milestone achievements and commercialization of JNJ-1900 (NBTXR3).
Elaborate on non-dilutive financing strategy
J&J amendment's impact on R&D funding?
Impact of device to drug reclassification?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Nanobiotix earnings date
H2 20251 Apr, 2026
Next Nanobiotix earnings date
H2 20251 Apr, 2026
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Nanobiotix S.A. is a biotechnology company that focuses on developing nanomedicine products for cancer treatment. The company's proprietary technology, NanoXray, involves nanoparticles that enhance the effects of radiotherapy by increasing the absorption of X-rays within cancer cells. This approach is designed to improve the precision and effectiveness of radiotherapy, potentially reducing side effects and improving patient outcomes. Nanobiotix's products are primarily in the clinical stages of development, and the company continues to advance its pipeline for various cancer types. The company is headquartered in Paris, France, and its shares are listed on the Euronext Paris.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage